B Cherreau

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
approximately 1 year in patients with aggressive ATL, including acute and lymphoma types. Allogeneic SCT promises to prolong survival in patients with aggressive ATL. However, HLAmatched related donors are frequently infected with HTLV-I, because mother-to-child transmission by breast feeding is a major route of HTLV-I acquisition. Restricting the use of(More)
  • 1